Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial

Ocul Immunol Inflamm. 2012 Apr;20(2):104-12. doi: 10.3109/09273948.2011.647228.

Abstract

Purpose: To assess the prevalence of hypotony in patients with severe forms of uveitis.

Methods: The Multicenter Uveitis Steroid Treatment (MUST) Trial, a randomized study, enrolled 255 patients. Patients with hypotony at the baseline visit were identified.

Results: Twenty (8.3%) of 240 patients with sufficient data had hypotony. Hypotony was more common in patients with uveitis ≥5 years duration (odds ratio [OR] = 5.0; p < .01), and in eyes with a history of ocular surgery (vitrectomy vs. none, OR = 3.1; p = .03). Hypotony was less in patients with older age of uveitis onset (>51 years vs. <51 years, OR = 0.1; p = .02), in Caucasian patients (OR = 0.1; p < .01) compared to African American patients. Hypotonous eyes were more likely to have visual impairment (OR = 22.9; p < .01).

Conclusions: Hypotony is an important complication of uveitis and more commonly affects African-American patients, those with uveitis onset at a younger age, and those with longer disease duration. It is associated with visual impairment.

Trial registration: ClinicalTrials.gov NCT00132691.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Animals
  • Black People / statistics & numerical data
  • Black or African American
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ocular Hypotension / drug therapy
  • Ocular Hypotension / epidemiology
  • Ocular Hypotension / ethnology
  • Ocular Hypotension / etiology*
  • Prevalence
  • Severity of Illness Index
  • Treatment Outcome
  • Uveitis / complications*
  • Uveitis / drug therapy
  • Uveitis / epidemiology
  • Uveitis / ethnology
  • Visual Acuity / drug effects
  • White People / statistics & numerical data
  • Young Adult

Substances

  • Adrenal Cortex Hormones

Associated data

  • ClinicalTrials.gov/NCT00132691